Fisher & Paykel Healthcare : Disclosure Document

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of isted issuer:

Date this disclosure made:

Date of last disclosure:

	Direct r	r senior manager giving disclosure
	only
Full name(s):
	Name of listed issuer:
	Name of r	lated body corporate (if applicable):
	Position h	ld in listed issuer:

useSummary of acquisition or disposal of relevant interest (excluding specified derivatives) Class of affected quoted financial products:

Nat re of the affected relevant interest(s):

For that relevant interest

personalFor that derivative,- Parties to the derivative:

Number he d in class before acquisition or disposal:

Number held in class after acquisition or disposal:

Current registered holder(s):

Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class	f underlying financial products:
Details	f affected derivative-
The n	ti	nal value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A tatement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expi y date of the derivative(if any):
The p ice specified in the terms of the derivative (if any):
Any oth	r details needed to understand how the amount of the consideration payable under
the d	rivative or the value of the derivative is affected by the value of the underlying
financial products:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

ForDetails of t ansactions giving rise to acquisition or disposal

T tal number of transactions to which notice relates:

Fisher & Paykel Healthcare Corporation Limited

7 March 2022

20 September 2021

Andrew Robert Donald Somervell

Fisher & Paykel Healthcare Corporation Limited

Not Applicable

Vice President - Products & Technology

Ordinary Shares

Beneficial interest in shares issued to a trustee under an Employee Share Scheme

67,800

67,888

Andrew Robert Donald Somervell

Andrew Robert Donald Somervell

Not Applicable

One

Details of transactions requiring disclosure-

Date of transaction:

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

	If the	issuer has a financial products trading policy that prohibits directors or senior
	managers from trading during any period without written clearance (a closed period)
	inc ude the following details-
	Whether relevant interests were aquired or disposed of during a closed period:
	Whether prior written clearance was provided to allow the aquisition or disposal to proceed
	duri	g the closed period:
	Date	f the prior written clearance (if any):
	only
Summary f other relevant interests after acquisition or disposal:
	use
	Class of quoted financial products:
	Nature of r levant interest:
	For that relevant interest,-
	Number held in class:
	C rrent registered holder(s):

For a derivative relevant interest,-

Type of derivative:

personalC rification

Detai s of derivative,-

The notion l value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any ther details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the di ector or senior manager is not a party to the derivative, the nature of the relevant inte est in the derivative:

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

ForDate f signature: r

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

28-Jan-20

Participation in Employee Share Purchase Scheme

Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited

$1,490.81

88

Not applicable

1. Options to acquire Ordinary Shares
2. 1. Peformance Share Rights
   2. 1. Beneficial
      2. Beneficial
      1. 144,323
      2. 42,631

Andrew Robert Donald Somervell

Not applicable

7 March 2022

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of isted issuer:

Date this disclosure made:

Date of last disclosure:

	Direct r	r senior manager giving disclosure
	only
Full name(s):
	Name of listed issuer:
	Name of r	lated body corporate (if applicable):
	Position h	ld in listed issuer:

useSummary of acquisition or disposal of relevant interest (excluding specified derivatives) Class of affected quoted financial products:

Nat re of the affected relevant interest(s):

For that relevant interest

personalFor that derivative,- Parties to the derivative:

Number he d in class before acquisition or disposal:

Number held in class after acquisition or disposal:

Current registered holder(s):

Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class	f underlying financial products:
Details	f affected derivative-
The n	ti	nal value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A tatement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expi y date of the derivative(if any):
The p ice specified in the terms of the derivative (if any):
Any oth	r details needed to understand how the amount of the consideration payable under
the d	rivative or the value of the derivative is affected by the value of the underlying
financial products:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

ForDetails of t ansactions giving rise to acquisition or disposal

T tal number of transactions to which notice relates:

Fisher & Paykel Healthcare Corporation Limited

7 March 2022

7 March 2022

Andrew Robert Donald Somervell

Fisher & Paykel Healthcare Corporation Limited

Not Applicable

Vice President - Products & Technology

Ordinary Shares

Beneficial interest in shares issued to a trustee under an Employee Share Scheme

90,887

90,922

Andrew Robert Donald Somervell

Andrew Robert Donald Somervell

Not Applicable

One

Details of transactions requiring disclosure-

Date of transaction:

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

	If the	issuer has a financial products trading policy that prohibits directors or senior
	managers from trading during any period without written clearance (a closed period)
	inc ude the following details-
	Whether relevant interests were aquired or disposed of during a closed period:
	Whether prior written clearance was provided to allow the aquisition or disposal to proceed
	duri	g the closed period:
	Date	f the prior written clearance (if any):
	only
Summary f other relevant interests after acquisition or disposal:
	use
	Class of quoted financial products:
	Nature of r levant interest:
	For that relevant interest,-
	Number held in class:
	C rrent registered holder(s):

For a derivative relevant interest,-

Type of derivative:

personalC rification

Detai s of derivative,-

The notion l value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any ther details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the di ector or senior manager is not a party to the derivative, the nature of the relevant inte est in the derivative:

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

ForDate f signature: r

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

28-Feb-22

Participation in Employee Share Purchase Scheme

Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited

$491.96

35

Not applicable

1. Options to acquire Ordinary Shares
2. 1. Peformance Share Rights
   2. 1. Beneficial
      2. Beneficial
      1. 109,826
      2. 25,656

Andrew Robert Donald Somervell

Not applicable

7 March 2022

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

	To NZX Limited; and
	Name of isted issuer:			Fisher & Paykel Healthcare Corporation Limited
	Date this disclosure made:			7 March 2022
	Date of last disclosure:			20 September 2021
	Direct r	r senior manager giving disclosure
	Full name(s):			Lewis George Gradon
	only
Name f listed issuer:		Fisher & Paykel Healthcare Corporation Limited
	Name of related body corporate (if applicable):
	Position h ld in listed issuer:			Chief Executive Officer
	Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
	Cla	of affected quoted financial products:		Ordinary Shares
	Nat	re of the affected relevant interest(s):			Beneficial interest in shares issued to a trustee
			under an Employee Share Scheme
	use
	For that relevant interest:
	Number held in class before acquisition or disposal:			562,280
	Number held in class after acquisition or disposal:			562,351
	personal
	Current registered holder(s):			Lewis George Gradon; Gradon Family Trust
	Registered holder(s) once transfers are registered:			Lewis George Gradon; Gradon Family Trust
	Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
	Type of affected derivative:			Not Applicable
	Class of underlying financial products:
	Details	f affected derivative:
	The n ti	nal value of the derivative (if any) or the notional amount of underlying financial
	products (if any):
	A tatement as to whether the derivative is cash settled or physically settled:
	Maturity date of the derivative (if any):
	Expi y date of the derivative(if any):
	The p ice specified in the terms of the derivative (if any):
	Any oth	r details needed to understand how the amount of the consideration payable
	und	r the derivative or the value of the derivative is affected by the value of the underlying
	financial products:
	For that derivative:
	Parties to the derivative:
	If the director or senior manager is not a party to the derivative, the nature of the relevant
	interest in the derivative:

ForDetails of transactions giving rise to acquisition or disposal

T tal number of transactions to which notice relates:

Details f transactions requiring disclosure:

Date of transaction:

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

One

28 February 2022

Participation in Employee Share Purchase Scheme

Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited

$1,495.92

71